Galafold Disease Interactions

Migalastat is substantially excreted by the kidneys. No dosage adjustment is required in patients with mild to moderate renal impairment (eGFR at least 30 mL/min/1.73 m2 and above). Migalastat is not recommended for use in patients with severe renal impairment or end-stage renal disease requiring dialysis. Systemic exposure was significantly increased in subjects with severe renal impairment (eGFR less than 30 mL/min/1.73 m2). Migalastat has not been studied in patients with Fabry disease who have an eGFR less than 30 mL/min/1.73 m2. Care is recommended when using this agent in patients with renal impairment.